Stockreport

FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome

Athersys, Inc.  (ATHX) 
Last athersys, inc. earnings: 11/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: athersys.com/press-releases
PDF In a Phase 1/2 study of MultiStem therapy for the treatment of ARDS, favorable tolerability data and meaningful potential benefits in mortality, ventilator-free days and [Read more]